Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

Three years ago, a randomized, double-blinded, placebo-controlled trial involving 236 subjects with mild to moderate COVID-19 found that Proxalutamide, an androgen receptor antagonist, significantly accelerated viral clearance and reduced time to clinical remission. On Day 7, 82% of the subjects in the Proxalutamide group had non-detectable SARS-CoV-2 compared to 31% in the placebo group. The average clinical remission time for patients treated with Proxalutamide was 4.2 ±5.4 days, compared to 21.8 ±13.0 days in the placebo group. The drug's efficacy may be due to its ability to suppress membrane-attached ACE2, blocking SARS-CoV-2 cell entry, among other potential mechanisms.